WO2012017141A1

WO2012017141A1 - Plant extract for the production of a slimming composition and method of control for slimming using such a composition

Info

Publication number: WO2012017141A1
Application number: PCT/FR2011/000430
Authority: WO
Inventors: Ngub Nding; Vincent Bourgeteau
Original assignee: Ephyla Sas
Priority date: 2010-07-21
Filing date: 2011-07-20
Publication date: 2012-02-09
Also published as: FR2962907B1; FR2962907A1

Abstract

The invention relates to an extract of a plant chosen from the group made up of the family Balanitaceae and the genus Vitellaria belonging to the family Sapotaceae for use thereof both as a control agent that is active on lipolysis and as an adipocyte differentiation inhibitor, for the production of a slimming composition.

Description

The present invention relates to the use of a plant extract selected from the group consisting of the Balanitaceae family and the Vitellaria genus for topical or oral cosmetic, pharmaceutical or nutraceutical compositions with lipidic slimming action.

One of the main objects of the present invention is the discovery, surprisingly and unexpectedly, of plant extracts capable of simultaneously stimulating lipolysis and inhibiting adipocyte differentiation, so as to optimize the slimming action by using two different biological and biochemical pathways from a single plant extract. Thus, the plant extracts selected from the group consisting of the family Balanitaceae and the genus Vitellaria stimulate the production of Zinc-alpha2-glycoprotein (ZAG), an LMF or lipid mobilization factor (ST RUSSELL Biochim Biophys. 2004 1636: 59-68) and inhibit the activity of Glucose-6-Phosphate Dehydrogenase (G6PDH), an enzyme involved in pre-adipocyte / adipocyte conversion (LM SHANTZ et al., PNAS 1989; 86: 3852-3856). ), as already demonstrated in EP0872244.

Part of the fat of the human body is stored as triglycerides in the cells of the hypoderm called adipocytes. Thinning accompanies a decrease in fat stored in adipocytes. The adipocytes are very active cells, they play a preponderant role in the control of the energy balance of the body. The adipocytes ensure the metabolism of fats. Fat anabolism, lipogenesis, results in a process of storage of fatty substances in the form of triglycerides under the action of enzymatic reactions inside the adipocytes. Lipogenesis is upregulated by insulin and is either by the uptake into the blood of fatty acids derived from lipoproteins (chylomicrons or very low density lipoproteins VLDL) and their hydrolysis by lipoprotein lipase, or by neosynthesis in the cell. from glucose. Lipogenesis thus leads to the storage of fats in the form of triglycerides in adipocytes. The catabolism of fats, lipolysis, results in a mobilization of triglycerides and their degradation under the action of enzyme, triglycerides lipases. They are activated by cyclic AMP. The cyclic AMP is regulated by Adenylate Cyclase, the latter is, moreover, repressed by 5 hydr hydrolysis via phosphodiesterase. Lipolysis thus leads to the release of fatty acids and the destocking of adipocytes.

If the metabolism is imbalanced in the direction of lipogenesis, then there occurs in the adipocytes an accumulation of triglycerides which gradually results in a thickening of the hypodermis. The skin deforms unevenly on the surface and gives the appearance of "orange peel". This deformity is unsightly, it affects the silhouette, it evolves in overweight and can lead to obesity.

To fight against this adiposity various axes have been explored and experimented to modulate the fat metabolism and privilege lipolysis, or to affect the storage capacity of adipocytes.

The different axes are:

- Or blocking the transport of glucose inside the adipocyte.

- The inhibition of lipoprotein lipases.

- The activation of triglyceride lipases (hormone-sensitive lipase) by stimulating the production of cyclic AMP under the control of adenylate

Cyclase, or by inhibition of are hydrolyzed by blocking phosphodiesterase.

Or the use of neuropeptide Y (NPY) receptor antagonists whose involvement in lipolysis has been demonstrated (P. Valet, J. Clin Invest, 1990, 85, 291-295).

Either the use of α 2 -adrenergic receptor antagonists or β-adrenergic receptor agonists to stimulate the production of cyclic AMP.

- Either the prevention of adipocyte differentiation by stimulation of G6PDH or by inhibition of metalloproteinases 2 and / or 9 according to the patent of CLARINS FR 286707A1. - Either the use of modulators Aquaporin adipose (AQPap) to reduce the volume of adipocytes and to increase the glycerol output according to the patent L'OREAL FR 2863492A1. The inventors of the present invention have now surprisingly and unexpectedly discovered that plant extracts selected from the group consisting of the family Balanitaceae and the genus Vitellaria act on both an agonist, ZAG, 3-adrenergic receptors, and on the prevention of adipocyte differentiation by inhibition of G6PDH activity.

Adipocyte differentiation consists of transforming the pre-adipocytes, themselves derived from dermal fibroblasts, which are non-functional in terms of lipid metabolism control, into functional adipocytes, that is to say capable of storing lipids by lipogenesis. and able to destock them by lipolysis.

The family Balanitaceae is represented by a single genus Balanites. The genus Balanites is mainly represented by the species Balanites aegyptiaca, Balanites maughamii and Balanites wilsoniana. These species are tropical trees and shrubs absent in America. They are characterized by their high content of sapogenins especially at the level of their fruits between 1 and 9%. Their seeds are oleaginous. The Balanitaceae family has already found cosmetic applications aimed at decreasing the melanin content and more generally aimed at lightening the skin as demonstrated and published by the applicant in patent FR 0902932. Therefore, it has not been revealed in the literature any use of at least one plant belonging to the family Balanitaceae in or for the preparation of a topical or oral composition intended for thinning.

It is precisely this type of use which is the subject of the present invention. The genus Vitellaria belongs to the family Sapotaceae, this genus consists of only one species Vitellaria paradoxa CF. Gaertn. This is a African tropical tree, also called Shea or Butyrospermum parkii. Its seeds are oleaginous, and provide shea butter. This plant is very widely known and used in various cosmetic applications. Traditionally women in West and Central Africa use shea butter topically to maintain and hydrate their skin and that of their baby. They also use this butter as a massage oil to relax muscles and soothe aching joints. In a more original way during the dry season during windy periods, and especially when the atmosphere is dusty, it is often observed that these African populations smear themselves inside the nostrils of shea butter to avoid getting sick. . In dermo-cosmetic products, for a very long time, shea butter has been widely used in the oily phases of oil-in-water emulsions, water-in-oil emulsions, balms or cosmetic oils. Furthermore, the patent FR 2859103 filed by SILAB describes an especially cosmetic active derived from shea cake having anti-radical and detoxifying properties; the patent FR 2912055 filed by IDENOV LAB describes a shea extract rich in gallic acid participating in calming skin irritation; patent FR 2698785 filed by THREL Jean-Noël shows that a shea extract can potentiate an activator of Adenylate Cyclase on a melanocyte model so as to contribute indirectly to the synthesis of melanin; in patent FR 2676645 SILAB demonstrates that unsaponifiables of shea butter can improve the effectiveness of sunscreens; in FR 2809011 SEDERMA discloses the use of cosmetically textile shea butter in encapsulated form; in FR2779645 patent SEDERMA demonstrates the use of shea combined with a coffee extract to promote healing and generate a soothing effect on the skin. Therefore, it has not been revealed in the literature any use of at least one plant belonging to the genus Vitellaria in or for the preparation of a topical or oral composition intended for thinning.

It is precisely this type of use which is the subject of the present invention. In a first embodiment of the invention, the composition is a topical or oral cosmetic, pharmaceutical or nutraceutical composition which contains at least one lipophilic vegetable fraction chosen from the group formed by the genus Vitellaria as an active agent against adiposity.

By active agent against adiposity, the inventors designate an active agent for reducing the adipose stock leading to a slimming effect. By active agent against adiposity, the inventors designate an active agent to slim down. In a second embodiment of the invention, the composition is a topical or pharmaceutical cosmetic composition which contains at least one lipohile vegetable fraction selected from the group consisting of the Balanitaceae family as an active agent against adiposity. In a third embodiment of the invention, the composition is a topical or oral cosmetic or pharmaceutical composition which contains as slimming and lipolytic active agent at least one lipophilic vegetable fraction chosen from the group formed by the genus Vitellaria.

In this embodiment, preferably, said or at least one of the active agent (s) active slimming is a lipophilic extract of plant seeds of the genus Vitellaria species paradoxa present in the composition at a concentration expressed as a percentage of weight relative to the total weight of the composition of between 0.0001 and 10%, preferably close to 0.05% according to the tested extract In a fourth embodiment of the invention, the composition is a topical or pharmaceutical cosmetic composition which contains as agent slimming and lipolytic active agent at least one lipophilic plant fraction selected from the group consisting of the family Balanitaceae.

In this embodiment, preferably, said or at least one of the slimming active agent (s) is a lipophilic extract of plant seeds of the Balanitaceae family, preferably genus Balanites species aegyptiaca present in the plant. composition at a concentration, expressed as a percentage by weight relative to the total weight of the composition, preferably between 0.0001 and 10%, preferably around 0.5%, depending on the extract tested.

Whatever the embodiment, the oral nutraceutical, pharmaceutical or cosmetic composition contains in each case at least one active agent formed of a lipophilic plant extract of seeds of the genus Vitellaria species paradox, incorporated in a nutraceutically or pharmaceutically acceptable vehicle compatible with oral ingestion, present in the composition at a concentration expressed as a percentage by weight relative to the total weight of the composition, preferably between 0.0001 and 100%, preferably around 1% depending on the extract tested.

The composition may furthermore comprise any additive usually used in the oral, nutraceutical or pharmaceutical cosmetic field, such as sequestering agents, antioxidants, preservatives, fillers, electrolytes, humectants, dyes, bases or acids. Uses, minerals, flavors, essential oils, nutraceutical or pharmaceutical active ingredients, lubricants, sweeteners, vitamins, essential fatty acids, vegetable or mineral oils, sweeteners. Of course, those skilled in the art will take care to choose this or these optional additional compounds and / or their amount in such a way that the advantageous properties of the composition according to the invention are not or substantially not impaired. These additives may be present in the composition in a proportion of from 0% to 99.9999% by weight relative to the total weight of the composition.

Whatever the embodiment, the topical composition contains in each case at least one active agent formed of a plant extract, as mentioned above incorporated in a pharmaceutically or cosmetically acceptable vehicle compatible with a topical application. The composition may furthermore comprise any additive usually used in the field of topical or pharmaceutical cosmetics, such as sequestering agents, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, bases or common acids, minerals, perfumes, essential oils, cosmetic active ingredients, moisturizers, vitamins, essential fatty acids, vegetable or mineral oils, silicones or their derivatives, sphingolipids, self-tanning compounds, soothing and protective agents for the skin. Of course, those skilled in the art will take care to choose this or these optional additional compounds and / or their amount in such a way that the advantageous properties of the composition according to the invention are not or substantially not impaired. These additives may be present in the composition in a proportion of from 0% to 99.9999% by weight relative to the total weight of the composition.

The topical or pharmaceutical cosmetic composition for controlling lipolysis and adipocyte differentiation is applicable topically and is in the form of an oil or lotion or an oil-in-water gel or emulsion or a water-in-oil emulsion. or cream.

The oral, nutraceutical or pharmaceutical cosmetic composition for controlling lipolysis and adipocyte differentiation is ingestable in the form of syrup, capsule, powder, ampoule, oral solution, oil, oil-in-water emulsion or water in oil, dough, chocolate or biscuit.

The pharmaceutical composition for controlling lipolysis and adipocyte differentiation according to the invention may be in injectable form. The injectable form of control is in the form of lotion or gel or emulsion oil in water or water in oil or oil.

The invention also relates to a method for controlling lipolysis and adipocyte differentiation for cosmetic purposes for thinning in a mammal comprising at least one step of parenteral administration of an effective amount of a selected lipophilic plant extract in the group formed by the family Balanitaceae and the genus Vitellaria. Examples of formulation below allow to illustrate the compositions according to the invention without however limiting the scope. Examples illustrating the activity of stimulating the production of Zinc-alpha2-glycoprotein (ZAG) and of inhibiting the activity of Glucose-6-Phosphate Dehydrogenase (G6PDH) of the various compositions according to the invention are also described, as well as examples illustrating the activity of stimulation of lipolysis. In the compositions below, the proportions of the various constituents are expressed as a percentage by weight relative to the total weight of the composition.

Example 1

An example of a cosmetic topical slimming composition in the form of a cream containing a lipohile extract of Balanites, in particular Balanites aegyptiaca, will be described.

The vegetable lipohil extract used is derived from the oilseed seeds of Balanites. These seeds are processed, in particular decocated to separate the shell from the kernel. The almond is then delipidated preferably by cold pressing or hot almonds, or by extraction with an apolar solvent such as, inter alia, hexane, or by supercritical CO2 extraction to separate the lipid fraction of almonds. This lipid fraction undergoes, either according to a first extraction method, an extraction with a polar alcoholic solvent such as, among others, ethanol or methanol containing between 0.01% and 10% of water, and preferably between 3 and 6% of water. water, or, according to a second mode of extraction, extraction with water in supercritical state. According to the first extraction method, by decantation, the supernatant of this extraction contains the active fraction of the lipohile extract according to the invention and can integrate the composition at a concentration preferably in the range 0.001% to 10% according to the second method of extraction, the directly obtained extract contains the active fraction of the lipohile extract according to the invention and can integrate the composition at a concentration preferably in the range 0.001% to 1%. According to any method of extraction, the extract obtained can thus be directly integrated into the topical cosmetic composition or, according to the first extraction mode can be dried by sublimation of the polar alcoholic solvent, in particular under vacuum to obtain a concentrated extract free of solvent. According to any method of extraction, the concentrated extract, devoid of solvent, is a more or less thick or viscous liquid which can set at room temperature, it is lipophilic and is incorporated in the oily or oily phase of the composition. This concentrated extract is incorporated into the composition at a concentration preferably in the range 0.001% to 1%.

The composition may have a formulation as follows:

Ingredients%

QSP Water

Xanthan Gum 0.7

Glyceryl Stearate 4.3

Ceteraryl alcohol and glucoside 2

cetearylic

Sesame oil 6

Sunflower oil 5

Dicaprylyl carbonate 3

Jojoba oil 1

Glycerin 1

Sorbic acid 0.35

Sodium benzoate 0.5

Vitamin E 0.2

Perfume 0.5

Lipophilic extract Balanites aegyptiaca 0.5

tested Example 2

An example of an "anti-pocket" cosmetic composition in the contour of the eyes that is in the form of serum and containing a lipohile extract of Vitellaria, in particular Vitellaria paradoxa, will be described. The vegetable lipohile extract used is derived from the oil seeds of Vitellaria. These seeds are processed, in particular decocated to separate the shell from the kernel. The almond is then delipidated, preferably after mechanical grinding, for example by cold or hot pressing of the almonds, or by extraction with an apolar solvent such as, inter alia, hexane, or by extraction with supercritical CO 2 in order to isolate the lipid fraction of almonds in whole or in part. This lipid fraction is then subjected to either an extraction with a polar alcoholic solvent, according to a first extraction method, such as, among others, ethanol or methanol containing between 0.01% and 10% of water, and preferably between 3 and 6%. of water, ie extraction with water in supercritical state, according to a second mode of extraction. By decantation, the supernatant according to the first extraction method, or the product directly extracted according to the second extraction mode, contains the active fraction of the lipohile extract according to the invention. According to any method of extraction, the extract obtained can thus be directly integrated, with or without a solvent, into the cosmetic composition or, according to the first extraction method, can be dried by sublimation of the polar alcoholic solvent, in particular under vacuum, to obtain a concentrated extract devoid of solvent. The concentrated extract, devoid of solvent, according to the first extraction method or the direct extract according to the second extraction method, is a more or less thick or viscous liquid which can set at room temperature, it is fat soluble and incorporates in the oily or oily phase of the composition. This concentrated extract according to the first extraction method or the direct extract according to the second extraction mode, is incorporated in the composition at a concentration, preferably in the range 0.0001% to 3%. The composition may have a formulation as follows:

EXAMPLE 3 An example of a slimming nutraceutical composition in the form of a powder containing a lipohile extract of Vitellaria, in particular Vitellaria paradoxa, will be described. According to the invention, according to current European regulations in force, only a lipohile extract of Vitellaria paradoxa can be the subject of a nutraceutical composition. The vegetable lipohile extract used is derived from the oil seeds of Vitellaria. These seeds are processed, in particular decocated to separate the shell from the kernel. The almond is then delipidated preferably after grinding mechanical, for example, by cold pressing or hot almonds, or by extraction with an apolar solvent such as, inter alia, hexane, or supercritical CO2 extraction to isolate the lipid fraction of almonds in all or part. This lipid fraction is then subjected to either an extraction with a polar alcoholic solvent, according to a first extraction method, such as, among others, ethanol or methanol containing between 0.01% and 10% of water, and preferably between 3 and 6%. of water, ie extraction with water in supercritical state, according to a second mode of extraction. By decantation, the supernatant according to the first extraction method, or the product directly extracted according to the second extraction mode, contains the active fraction of the lipohile extract according to the invention. According to any method of extraction, the extract obtained can thus be directly integrated, with or without a solvent, into the cosmetic composition or, according to the first extraction method, can be dried by sublimation of the polar alcoholic solvent, in particular under vacuum, to obtain a concentrated extract devoid of solvent. The concentrated extract, devoid of solvent, according to the first extraction method or the direct extract according to the second extraction method, is a more or less thick or viscous liquid which can set at room temperature, it is fat soluble and incorporates in the oily or oily phase of the composition. This concentrated extract according to the first extraction method or the direct extract according to the second extraction mode, is incorporated in the composition at a concentration, preferably in the range 0.0001% to 3%.

The composition may have a formulation as follows: Dehydrated acerola pulp 99% Lipohile extract Vitellaria paradoxa tested 1%

Example 4

An example of a slimming nutraceutical composition in the form of dark chocolate and containing a lipohil extract of Vitellaria, in particular of Vitellaria paradoxa will be described. According to the invention, according to current European regulations in force, only a lipohile extract of Vitellaria paradoxa can be the subject of a nutraceutical composition.

The vegetable lipohile extract used is derived from the oil seeds of Vitellaria. These seeds are processed, in particular decocated to separate the shell from the kernel. The almond is then delipidated, preferably after mechanical grinding, for example by cold or hot pressing of the almonds, or by extraction with an apolar organic solvent such as, inter alia, hexane, or by extraction with supercritical CO 2 so to isolate the lipid fraction of almonds in whole or in part. This lipid fraction is then subjected to either an extraction with a polar alcoholic solvent, according to a first extraction method, such as, among others, ethanol or methanol containing between 0.01% and 10% of water, and preferably between 3 and 6%. of water, ie extraction with water in supercritical state, according to a second mode of extraction. By decantation, the supernatant according to the first extraction method, or the product directly extracted according to the second extraction mode, contains the active fraction of the lipohile extract according to the invention. According to any method of extraction, the extract obtained can thus be directly integrated, with or without a solvent, into the cosmetic composition or, according to the first extraction method, can be dried by sublimation of the polar alcoholic solvent, in particular under vacuum, to obtain a concentrated extract devoid of solvent. The concentrated extract, devoid of solvent, according to the first extraction method or the direct extract according to the second extraction method, is a more or less thick or viscous liquid which can set at room temperature, it is fat soluble and incorporates in the oily or oily phase of the composition. This concentrated extract according to the first extraction mode or the direct extract according to the second extraction mode is incorporated in the composition at a concentration, preferably in the range 0.0001% to 100%.

The composition may have a formulation as follows: Cocoa powder

Cocoa butter

Leaf extract Stevia rebaudiana

Lipohil extract Vitellaria paradoxa tested As illustrated by the results of activity below, the compositions containing extracts of Balanites aegyptiaca (Balanitaceae) and Vitellaria paradoxa (Sapotaceae) are compositions that induce destocking of fats in mammals. This destocking is explained by stimulation of lipolysis due to the increased production of Zinc-alpha 2-glycoprotein (ZAG), an LF or lipid mobilization factor which binds to the adrenergic β3 adrenergic receptors. a G protein so as to activate Adenylate Cyclase. Adenylate Cyclase then transforms ΑΤΡ into cAMP that activates a protein kinase. This protein kinase activates a lipase that degrades the triacylglycerol stored in fatty acids. ZAG thus activates the enzymatic cascade which leads to lipolysis. ZAG therefore stimulates lipolysis directly by overexpressing cAMP. This destocking of fats is also explained by inhibition of differentiation of pre-adipocytes by inhibition of Glucose 6 phosphodihydrogenase (G6PDH).

The uses of these compositions are diverse and varied.

According to a first mode of application, in topical applications, the extracts according to the invention can be used in slimming, lipolytic, anti-cellulite, firming, toning, anti-puffiness products under the eyes, and more generally in products intended for to improve and refine the silhouette, the face and the bust. These compositions may be in the form of capsules glued to textile fibers of slimming garments or of textile impregnated with capsules in contact with the skin or of polymers impregnated with capsules in contact with the skin, of capsules incorporated in massage products, of massage oils, oil-in-water emulsion, water-in-oil emulsion, serum, lotion, gel, soap, in dermocosmetic products, in makeup products, as co-active in firming, tensor and anti-aging products.

To be effective, and taking into account the persistence of their activity, non-rinsed cosmetic products comprising these active ingredients are to be used preferably at least twice a week in a three-month course. The rinsed cosmetic compositions comprising these active ingredients are to be used preferably at least twice a day, in course of three months.

Cosmetics including these assets can be used every day.

According to a second embodiment, Per os, in the nutraceutical field, only the lipophilic extract of Vitellaria paradoxa can be used in a "food" manner in view of current European regulations, and therefore incorporate slimming compositions according to the invention. . According to the second mode of application, the lipohile extract of Vitellaria paradoxa according to the invention may incorporate slimming compositions, or against adiposity, nutraceuticals and pharmaceuticals. These compositions may be in the form of powders, gels, lotions, pastes, gums, chocolates, capsules, capsules, oil-in-water emulsions, water-in-oil emulsions, oils or bulbs.

According to a third mode of application, by injection, in the pharmaceutical field, the extracts according to the invention can incorporate injectable compositions. These compositions may be in the form of extemporaneously dilutable powders, gel, lotion, serum, oil-in-water or water-in-oil emulsion.

The extracts selected for the demonstration are extracts from a hydroalcoholic extraction of the lipid fraction of the seeds of the plants, then concentrated by vacuum evaporation of ethanol and water using a "rotavapor" system.

Thus, the lipohile extract of the lipid fraction of Balanites aeqyptiaca seeds has a composition as follows: Lipid fraction of the seed 50% Ethanoi 96 ° 50%

The composition being expressed as a percentage by weight relative to the total weight of said composition.

This extract is kept stirring in the dark for 4 hours at room temperature. This extract is allowed to settle in the dark at room temperature for 24 hours. The supernatant is recovered.

The supernatant is then concentrated by evaporation of the 96 ° ethanol in a "rotavapor" system at 40 ° C. under vacuum. The resulting concentrated extract is referred to in the following as "LIPOHILE EXTRACT BALANITES AEGYPTIACA TEST".

The lipohile extract of the lipid fraction of the seeds of Vitellaria paradoxa has a composition as follows:

Lipid fraction of the seed 50%

Ethanoi 96 ° 50%

The supernatant is then concentrated by evaporation of the 96 ° ethanol in a "rotavapor" system at 40 ° C. under vacuum. The resulting concentrated extract is referred to in the following as "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST".

The following results illustrate the dose effect of the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST" and "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST" for their ability to modulate the production of ZAG in a model of normal adult human epidermal keratinocytes. Monolayers of normal human keratinocytes were obtained by culturing cells from an abdominoplasty performed in a 45-year-old woman. The keratinocytes were incubated for 48 hours at 37 ° C, under humid atmosphere and at 5% CO2, in absence (control) or in the presence of dexamethasone at 10 μ (reference product) or in the presence of increasing concentrations of test assets. These concentrations (V / V) are expressed in volume of the active relative to the total volume of the incubation medium in which the asset is stabilized.

"LIPOHILE EXTRACT BALANITES AEGYPTIACA TEST" = SNHBCO2: SNHBCO2 → 0.001; 0.005; 0.01% (VA /)

"LIPOHILE EXTRACT VITELLARIA PARADOXA TEST" = SNBKSTBF: SNBKSTBF → 0.001; 0.005; 0.01% (V / V)

The "LIPOIL EXTRACT BALANITES AEGYPTIACA TEST" = SNHBCO2 is first diluted to 50% in DMSO (VA /), to be diluted in the culture medium. The "LIPOHIL EXTRACT VITELLARIA PARADOXA TEST" = SNBKSTBF is first diluted to 10% DMSO (P / V), to be diluted in the culture medium.

At the end of the incubation period, the ZAG is quantified in the culture media using a sensitive and specific ELISA kit, and the proteins contained in the cell lysates are quantified by a spectrocolorimetric method using blue Coomassie (Bradford M., 1976 Anal Biochem., 72, 248-254). The results are given in the form of a ratio "ng of ZAG / mg of total proteins of the cell layer" (averages +/- standard deviation, SD). The statistical significance of the differences observed between the conditions "control" and "reference product" or "DMSO" is evaluated by a Student's test (Student t-test, p <0.05). The statistical significance of the observed differences between the conditions "control" and "product under test" is evaluated product by product, by a one-way analysis of variance (One Way ANOVA), followed, where necessary, by a Holm-Sidak or Dunn's test (p <0.05). The results presented in FIG. 1 relate to the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TESTE" and "EXTRACT LIPOHILE VITELLARIA". PARADOXA TEST "and show that under the experimental conditions retained after 48 hours of incubation, the active ingredients" EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST "and" EXTRACT LIPOHILE VITELLARIA PARADOXA TEST "induce a significant increase in the keratinocyte production of ZAG. These results are validated by the fact that dexamethasone at 10 μ, used as reference product, significantly increased, as expected, the keratinocyte production of ZAG.

- "SNHBCO2" at 0.005% → + 42.3% (p <0.05)

- "SNHBCO2" at 0.01% → + 30.1% (p <0.05) - "SNBKSTBF" at 0.005% → + 14.5% (p <0.05)

- "SNBKSTBF" at 0.01% → + 55.7% (p <0.05)

- "Dexamethasone" at 10 μΜ → + 27% (p <0.05)

The results below illustrate the dose effect of the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST" and "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST" for their ability to modulate the activity of G6PDH in an acellular IN VITRO model. The Glucose-6-phosphate dehydrogenase used is from SIGMA-ALDRICH. G6PDH is incubated with a solution of glucose, ATP, NAD and hexokinase, with or without the active ingredients tested:

hexokinase

Glucose + ATP ► Glucose-6-Phosphate + ADP

G6PDH

G6PD + NAD ► 6-PHOSPHOGLUCONATE + NADH

The change in absorbance at 340 nm is directly proportional to the activity of G6PDH. The G6PDH solution is incubated for 5 minutes at ambient temperature in the presence of substrates, and in the absence (buffer alone) or in the presence of EDTA (reference product) or increasing concentrations of active ingredients.

"LIPOHILE EXTRACT BALANITES AEGYPTIACA TEST" = SNHBC02: SNHBC02 → 0.001; 0.005; 0.01; 0.05; 0.1; 0.5 and 1% (VA /)

These concentrations (VA /) are expressed as the volume of the active relative to the total volume of the incubation medium in which the asset is stabilized.

"LIPOHILE EXTRACT VITELLARIA PARADOXA TEST" = SNBKSTBF: SNBKSTBF → 0.001; 0.005; 0.01; 0.05; 0.1; 0.5 and 1% (W / V)

These concentrations (PAZ) are expressed by weight of the active ingredient relative to the total volume of the incubation medium in which the active agent is stabilized.

A "white product" is produced in the absence of G6PDH, for each of the concentrations of the products tested to take into account a possible absorbance at 340 nm of the test assets.

The "LIPOIL EXTRACT BALANITES AEGYPTIACA TEST" = SNHBCO2 is first diluted to 50% in DMSO (VA /), to be diluted in the culture medium. The "LIPOHIL EXTRACT VITELLARIA PARADOXA TEST" = SNBKSTBF is first diluted to 10% of DMSO (P V), to be diluted in the culture medium.

The amplitude of the enzymatic reaction is evaluated after 5 minutes of incubation in the presence of substrate and of the products under test, by spectrocolorimetry by reading the absorbance of the reaction mediums at 340 nm. For each concentration tested, the effect of the test product on the activity of G6PDH is calculated using the following formula: Q, [OD; *; in the presence of. ^" inhibitor _χ 100

I DOs his absence of 1 mlnbitew

The results are given as a percentage of G6PDH activity relative to the control (averages +/- standard deviation, SD). The statistical significance of the differences observed between the conditions "Control" and "reference product" or "DMSO 1%" is evaluated by a Student t-test (p <0.001) and a one-way analysis of variance (One Way ANOVA), followed by a Holm-Sidak test (p: <0.05). The statistical significance of the observed differences between the conditions "control" and "product under test" is evaluated product by product, by a one-way analysis of variance (One Way ANOVA), followed, where necessary, by a Holm-Sidak test (p <0.05).

The results presented in FIG. 2 relate to the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST" and "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST" and show that under the experimental conditions selected after 5 minutes of incubation, the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TESTE" and "LIPOHILE EXTRACT VITELLARIA PARADOXA TESTE" significantly inhibit the activity of G6PDH. These results are validated by the fact that the 5 mM EDTA, used as a reference product, significantly inhibited the enzyme reaction in an expected manner after 5 minutes of incubation.

- "SNHBCO2" at 0.005% → - 39% (p <0.05)

- "SNHBCO2" at 0.01% → - 47.8% (p <0.05) - "SNBKSTBF" at 0.01% → - 35.5% (p <0.05)

- "SNBKSTBF" at 0.05% → - 74.3% (p <0.05)

- "EDTA" at 5 μΜ → - 83% (p <0.05)

The following results illustrate the dose effect of the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST" and "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST" for their ability to modulate lipolytic activity in a model of normal adult human adipocytes in suspension. Human adipocytes were dissociated from a tummy tuck performed in a 62-year-old woman, and then incubated with or without test assets. The Adipocytes were incubated for 2 hours at 37 ° C., with shaking, in the absence (medium incubation alone) or in the presence of the reference products, or with increasing concentrations of the products under test. The keratinocytes were incubated for 48 hours at 37 ° C. C, in a humid atmosphere and at 5% CO2, in absence (control) or in the presence of dexamethasone at 10 μΜ (reference product) or in the presence of increasing concentrations of the test substances.

"LIPOHILE EXTRACT BALANITES AEGYPTIACA TEST" = SNHBCO2:

SNHBCO2 → 0.001; 0.01; 0.1% (W / V)

These concentrations (PA) are expressed as the weight of the active ingredient relative to the total volume of the incubation medium in which the active agent is stabilized.

"LIPOHILE EXTRACT VITELLARIA PARADOXA TEST" = SNBKSTBF: SNBKSTBF → 0.001; 0.01; 0.1% (W / V)

SNHBCO2 is prepared from a 50% stock solution in DMSO (VA /), then diluted directly in the culture medium, with a maximum concentration of DMSO of 0.01% (VA /). SNBKSTBF is prepared from a 10% stock solution in DMSO (PA /), and then diluted directly in the culture medium with a maximum concentration of DMSO of 1% (VA /).

The reference activators used with respect to lipolytic activity on adipocytes are caffeine and theophylline at 10 ^-4 M.

At the end of the incubation period, the non-esterified fatty acids (EAFA) are quantified in the incubation media using a sensitive and specific spectrophotometric technique.

The results are given in the form of concentrations (in μΜ) of AGNE present in the incubation medium of the adipocytes (average +/- standard derivation, SD). The statistical significance of the differences observed between the conditions "control" and "reference product" is evaluated by a Student's test (Student t-test, p <0.001). Significance statistic of the differences observed between the conditions "Witness" and "Products under test", is evaluated product by product, by a one-way analysis of variance (One Way ANOVA), followed, when this requires a test from Holm-Sidak (p <0.05).

The results presented in FIG. 3 relate to the active ingredients "EXTRACT LIPOHIL BALA ITES AEGYPTIACA TEST" and "EXTRACT LIPOHILE VITELLARIA PARADOXA TEST" and show that under the experimental conditions retained after 2 hours of incubation at 37 ° C., the active ingredients "EXTRACT LIPOHILE BALANITES AEGYPTIACA TEST "and" EXTRACT LIPOHIL VITELLARIA PARADOXA TEST "significantly increase lipolysis. These results are validated by the fact that caffeine and theophylline, used as reference products, significantly increased, as expected, the release of AGNE in the incubation medium of the adipocytes in suspension.

- "SNHBCO2" at 0.01% → + 34% (p <0.05)

- "SNHBCO2" at 0.1% → + 64% (p <0.05)

- "SNBKSTBF" at 0.001% → + 60% (p <0.05)

- "SNBKSTBF" at 0.01% → + 70% (p <0.05) - "Caffeine" at 10 ^"4 M → + 67% (p <0.001)

- "Theophylline" at 1 (T * → + 125% (p <0.001)

Claims

1. Plant extract selected from the group consisting of the family Balanitaceae and the genus Vitellaria from the family Sapotaceae for its use both as a lipolysis stimulating agent and as an inhibitor of adipocyte differentiation for the manufacture of action composition slimming.

2. Slimming composition, characterized in that it contains both as active agent on lipolysis and as an inhibitor of adipocyte differentiation at least one plant extract selected from the group consisting of the family Balanitaceae and the genus Vitellaria of the Sapotaceae family.

3. slimming composition according to claim 2, characterized in that, said composition is a pharmaceutical composition which contains at least one plant extract selected from the group consisting of the family Balanitaceae and the genus Vitellaria family Sapotaceae as agent active on lipolysis and as an inhibitor of adipocyte differentiation, in an amount effective to treat or prevent disgrace of adiposity such as "orange peel" or being overweight.

4. slimming composition according to claim 2, characterized in that, said composition contains at least one plant extract selected from the group consisting of the family Balanitaceae and the genus Vitellaria family Sapotaceae as an active agent on lipolysis and as an inhibitor of adipocyte differentiation, in an amount effective to treat or prevent disgrace of adiposity such as "orange peel" or overweight silhouette.

5. slimming composition according to claim 2, characterized in that, said composition is a nutraceutical composition which contains at least one plant extract selected from the genus Vitellaria of the Sapotaceae family as an active agent on lipolysis and as an inhibitor of differentiation adipocyte, in an amount effective to treat or prevent disgrace of adiposity such as "orange peel" or overweight silhouette.

6. Slimming composition according to claim 3, characterized in that it is applicable by injection and is in the form of gel, lotion, oil in water emulsion or water in oil.

7. Slimming composition according to claim 4, characterized in that it is applicable topically and is in the form of capsules embedded in massage products, massage oils, oil-in-water emulsion, emulsion water in oil, lotion, gel.

8. slimming composition according to claim 5, characterized in that it is applicable orally and is in the form of powders, gels, pastes, chocolates, capsules, oil-in-water emulsions, emulsion water in oil, oils, bulbs.

9. slimming composition according to claims 3 and 4, characterized in that said or at least one of the active agent (s) is a lipophilic extract of plant seeds of the family Balanitaceae preferably genus Balanites species aegyptiaca present in said composition at a concentration expressed in percentages by weight relative to the total weight of the composition of between 0.0001% and 1%, preferably close to 0.1% according to the extract tested or an extract of plant seeds of the genus Vitellaria belonging to the Sapotaceae family preferably paradoxa species present in said composition in a concentration expressed in percentages by weight relative to the total weight of the composition of between 0.0001% and 3%, preferably close to 0.05% according to the extract tested.

10. Slimming composition according to claim 5, characterized in that said active agent is an extract of plant seeds of the genus Vitellaria belonging to the Sapotaceae family, preferably paradoxa species present in said composition in a concentration expressed in percentages by weight relative to total weight of the composition of between 0.0001% and 3%, preferably around 1% according to the extract tested.

11. A method for controlling cosmetic purposes for thinning comprising at least one step of parenteral administration of an effective amount of a plant extract selected from the group consisting of the family Balanitaceae and the genus Vitellaria belonging to the family Sapotaceae.